A5012242496- Ovarian cancer diagnosis and treatment
- Renal Diseases and Glomerulopathies
- Angiogenesis and VEGF in Cancer
Universität Hamburg
2020-2022
University Medical Center Hamburg-Eppendorf
2020-2022
Klinik und Poliklinik für Neurologie
2020
At present, maintenance therapy with the antiangiogenic agent bevacizumab or PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response different therapies remains a major challenge. In present study we analyzed predictive potential vascular endothelial growth factor C (VEGF-C) identify patients that might benefit from an therapy.101 primary epithelial were...
Zielsetzung Das epitheliale Ovarialkarzinom (EOC) wird wegen fehlender Frühsymptome meist im fortgeschrittenen Tumorstadium diagnostiziert, was i.d.R. mit einer schlechten Gesamtprognose einhergeht.